Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside

Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.

Vertex Pharmaceuticals (VRTX) has been on a tear, recently touching the top of its 52-week range. For owners of the stock, that raises a classic question: do you let it ride, or do you lock in some value? There is a third way, a trade that pays you a meaningful income right now, cash you keep regardless of what happens next, in exchange for setting a defined, higher exit price on your shares.

9.0% annualized income on VRTX shares you already own, with 15% of upside room, by selling a covered call.

• You own (or buy) 100 shares of VRTX near today’s price of $529.59.
• Sell one call option on VRTX expiring 6/17/2027, with a strike price of $610, about 15% above today.
• Collect roughly $4,500 in premium up front per contract (each contract covers 100 shares), which you keep no matter what the stock does.
• That premium is about 9.0% annualized on the $52,959 of stock, income you earn just for holding.
• If VRTX finishes above $610, your shares are called away at $610. Counting the premium, your total return works out to about 25% annualized, but you give up any gains above the strike.

Called Away Or Not, You Pocket The Premium

If VRTX finishes below $610 on 6/17/2027, the call expires worthless, and you keep the full $4,500 premium and all your shares. That is about 8.5% over 346 days, income earned just for holding, and you are free to sell another call.

If VRTX finishes above $610, your 100 shares are called away at $610. You still keep the $4,500 premium, and counting it as your total gain works out to about 24%, a healthy exit. The cost of the trade is that any gain above $610 is no longer yours. And if the stock instead falls, you keep the premium but still ride the shares down, cushioned only slightly.

So the whole trade comes down to one thing: how much of that upside are you really likely to give up, and would you be content to sell at that higher price?

What Upside Would You Be Handing Over?

The real cost of this trade is the upside you cap. So, how much are you giving up? The bull case is that Vertex is on the cusp of its next great act. The company’s emerging renal franchise, led by a specific drug in development, is being positioned by management as a potential growth engine that could be “as big if not larger than CF.” The drug’s “sparkling” data, showing a 52% reduction in a key disease marker, is the kind of catalyst that could power the stock well beyond your exit price, leaving you with a solid gain but a dose of seller’s remorse.

On the other hand, there’s a reason to believe the best of the run is behind it. The foundational cystic fibrosis business, while still a cash-flow machine, is maturing. Management itself admits that improving on its latest blockbuster is “getting really, really tough.” The recent discontinuation of a promising mRNA therapy, VX-522, was a tangible setback. This view suggests the core engine is slowing, making a trade that generates immediate income in exchange for foregoing some potential blue-sky upside a savvy move. The decision boils down to whether you believe the new pipeline can seamlessly pick up the torch from the old one. The key thing to watch is the commercial launch and early uptake of this new drug.

See The Covered-Call Income On A Stock You Own

You may not own VRTX, but you almost certainly own something that could be paying you. Our Covered Call Finder lets you type in a stock, or a few, and instantly see the income a covered call could generate on each, then dial the strike up or down with a slider to balance more income against more upside. It is the quickest way to see what the names in your own portfolio could pay.

One step out from a single name: a biotech ETF like IBB owns the whole biotech group at once, so no single company can sink you. It still rises and falls with that one theme, which is exactly the gap the portfolio below closes.

Income Is Nice. Concentration Is Not.

Selling calls can squeeze income from a holding – but it does nothing about the bigger risk, which is how much of your wealth sits in that one name. If a single stock dominates your portfolio, the income is a rounding error next to the drawdown risk, and selling to diversify means a tax bill. There is a way to protect the position and diversify out tax-efficiently.